For Immediate Release:
January 11, 2026
The U.S. Food and Drug Administration today announced it is sharing information about the agencys flexible approach to overseeing chemistry, manufacturing an… [+3405 chars]
FDA Increases Flexibility on Requirements for Cell and Gene Therapies to Advance Innovation - fda.gov
The U.S. Food and Drug Administration today announced it is sharing information about the agency’s flexible approach to overseeing chemistry, manufacturing and control (CMC) requirements for cell and gene therapies (CGT).
By:Office of the Commissioner
Source:FDA.gov
Published:
Related News
Drug pricing, patent losses and deals: Here's what pharma execs see ahead in the industry - CNBC
Big pharma is grappling with new drug pricing deals and roughly $300 billion in potential lost revenue from patent expirations of blockbuster drugs.
CNBC•Annika Kim Constantino
Danish pension fund to sell $100 million in Treasuries, citing 'poor' U.S. government finances - CNBC
AkademikerPension's move comes amid increasing tensions between Denmark and the U.S. over Greenland.
CNBC•Alex Harring
S&P 500 Sheds $750 Billion—Greenland’s Estimated Value—On Trump’s Threats, Economist Says - Forbes
Trump has escalated his campaign for U.S. control over the Danish territory.
Forbes•Ty Roush